Alterity Therapeutics Releases New Findings on MRI Endpoint
- Innovative publication in Annals of Clinical and Translational Neurology showcases MSA Atrophy Index for Multiple System Atrophy progression tracking -
MELBOURNE, Australia and SAN FRANCISCO - Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a pioneering biotechnology firm focused on neurodegenerative diseases, recently revealed transformative findings regarding their Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study. This significant research has been documented in a peer-reviewed edition of Annals of Clinical and Translational Neurology.
The publication, titled "The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy," elaborates on the deployment of cutting-edge deep learning methods, which leverage artificial intelligence to delineate the neuroanatomy of critical regions within the brain. This innovative approach has yielded a groundbreaking brain atrophy measure crucial for tracking disease progression in MSA patients over the course of a year, correlating these measures with clinical indicators of disease severity.
“This exciting research utilizes advanced technology utilized in the bioMUSE study, enhancing beyond traditional MRI techniques in assessing brain volume in MSA patients,” remarked David Stamler, M.D., CEO of Alterity. “Thanks to the ingenuity and technical expertise of our partners at Vanderbilt University Medical Center, we now possess superior instruments for both diagnosing MSA and monitoring brain atrophy over time. Notably, we found that statistically significant reductions in brain volume over twelve months were linked to clinical declines in the disease, reinforcing the value of advanced neuroimaging techniques in evaluating MSA, which have been integrated into our Phase 2 clinical program.”
“While prior MRI research has identified brain volume declines in regions impacted by MSA, consistently monitoring these changes has posed significant challenges. The MSA Atrophy Index enhances our understanding of the condition's progression and supports utilizing brain atrophy metrics to evaluate disease-modifying treatments. These advancements promise a more personalized approach to diagnosis and management of MSA. We are eager to apply this vital technology for patient selection and tracking disease progression in our Phase 3 clinical trials,” Dr. Stamler added.
Offering an objective, quantifiable assessment of brain atrophy in regions commonly affected by MSA, the MSA-AI streamlines the evaluation of disease progression and treatment responses. This technology is especially crucial in MSA, where early diagnosis can be problematic due to symptom overlap with Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). The MSA-AI’s phenotype-independent analysis allows its application to both subtypes of MSA, MSA-P and MSA-C, thereby extending its utility despite varying atrophy patterns. By providing a standardized measure of structural changes, the MSA-AI may enable earlier, more precise diagnoses and improve clinical trial participant selection.
By incorporating a longitudinal cohort from bioMUSE alongside a cross-sectional group of individuals with more advanced MSA, the researchers were able to amass data that represents a wide spectrum of clinical severity and atrophy characteristics. This dual design empowers local and broader assessments of both early-stage and established disease, thereby augmenting the applicability of the findings. MSA patients exhibited significantly lower MSA-AI scores in comparison to all other diagnostic categories, indicating pronounced reductions in brain volumes.
The MSA-AI distinctly differentiated MSA patients from related synucleinopathies, achieving highly significant p-values. Correlations with baseline clinical severity and predictions of disease progression further underscore the MSA-AI's value in clinical settings, demonstrating a comprehensive view of the MSA trajectory. Longitudinal reductions in MSA-AI were also associated with worsening clinical scores over a year, reinforcing its prognostic significance.
Exploring the bioMUSE Study
The bioMUSE initiative is a critical natural history study designed to meticulously trace the trajectory of individuals afflicted with MSA, a condition currently lacking an approved therapeutic solution. Conducted in collaboration with Vanderbilt University Medical Center, the study, under the direction of Daniel Claassen, M.D., M.S., seeks to quantify the progression of MSA using the dense data collected for optimizing Alterity's ongoing randomized ATH434-201 Phase 2 clinical trial.
The bioMUSE study has so far enrolled about 20 individuals displaying clinically probable or established MSA. The insights garnered from this initiative continue to pave the way for identifying crucial biomarkers suitable for evaluating treatment engagement and preliminary efficacy, as well as providing essential clinical insights reflective of MSA progression within patient groups currently participating in the Phase 2 clinical investigation.
Understanding Multiple System Atrophy
Multiple System Atrophy (MSA) is recognized as a rare yet rapidly progressing neurodegenerative disorder linked to the dysfunction of the autonomic nervous system and various motor impairments. Symptoms arise from the gradual degeneration and death of diverse nerve cells within the brain and spinal cord, severely impacting quality of life. MSA presents with a unique combination of movement slowing, rigidity, and autonomic dysfunction, leading to significant challenges in daily living. Additionally, the accumulation of the protein ?-synuclein in glial cells is a pathological hallmark of this condition, with MSA commonly affecting over 15,000 individuals.
At present, while certain symptoms can be managed with medications, there remains a dire lack of treatments capable of slowing disease progression or delivering definitive cures, highlighting the urgent need for ongoing research and innovation in this field.
About Alterity Therapeutics Limited
Alterity Therapeutics, a clinical-stage biotechnology company, is committed to shaping a brighter future for those impacted by neurodegenerative conditions. With a primary focus on developing disease-modifying treatments for Parkinson's disease and associated disorders, Alterity has recently reported encouraging results concerning ATH434 in its Phase 2 trial for MSA. In addition, the company has established a comprehensive drug discovery platform, producing patentable chemical compounds aimed at treating the underlying mechanisms of neurological diseases. Headquartered in Melbourne, Australia, and San Francisco, California, Alterity continues to advance its mission. For more information, consider visiting their official website.
Frequently Asked Questions
What is the MSA Atrophy Index?
The MSA Atrophy Index (MSA-AI) is a novel neuroimaging measure that quantifies brain atrophy in patients with Multiple System Atrophy, providing essential data for tracking disease progression.
How does the MSA-AI improve diagnosis?
The MSA-AI enhances diagnosis by offering an objective measure of brain atrophy that distinguishes MSA from related disorders, thereby facilitating earlier and more accurate identification of the disease.
What is the significance of the bioMUSE study?
The bioMUSE study is crucial as it collects extensive data on MSA progression, aiding in the understanding of clinical characteristics, which ultimately supports the development of targeted therapies.
How does Alterity Therapeutics contribute to MSA treatment?
Alterity Therapeutics focuses on developing innovative, disease-modifying therapies to improve the lives of individuals affected by MSA and related neurodegenerative disorders.
What are the next steps for Alterity Therapeutics?
Alterity aims to leverage the findings from the bioMUSE study and MSA-AI in upcoming clinical trials, enhancing patient outcomes through refined diagnostic and treatment strategies.
